Dorzagliatin Showed Sustained Remission in an Observational Study after Discontinuation of Treatment in T2D Patients Who Achieved Good Glycemic Control with Dorzagliatin Monotherapy

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• Dorzagliatin is an oral dual-acting glucokinase activator, which has shown glycemic control and improvements in insulin secretion and β-cell function.
• DREAM was an observational, non-pharmacological, non-interventional diabetes remission study to observe whether 69 patients who had completed a Phase 3 trial and achieved good glycemic control were able to achieve remission without any antidiabetic medication.
• At Week 52, 36 subjects maintained stable glycemic control; remission rate was 65.2% (52.0% according to the ADA consensus definition).
• Improvements of β-cell function and insulin resistance were sustained during DREAM.
• DREAM observed sustained glycemic control in a high proportion of subjects after withdrawal of dorzagliatin monotherapy, indicating that improvements of early-phase insulin secretion and β-cell function may be a potential mechanism for diabetes remission.